Liu Bochao, Wu Ze, Liang Chaolan, Lu Jinhui, Li Jinfeng, Zhang Ling, Li Tingting, Zhao Wei, Fu Yongshui, Hou Shuiping, Tang Xi, Li Chengyao
Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Guangzhou Blood Center, Guangzhou, China.
Front Microbiol. 2021 Aug 23;12:692831. doi: 10.3389/fmicb.2021.692831. eCollection 2021.
Since December 2019, a novel coronavirus (SARS-CoV-2) has resulted in a global pandemic of coronavirus disease (COVID-19). Although viral nucleic acid test (NAT) has been applied predominantly to detect SARS-CoV-2 RNA for confirmation diagnosis of COVID-19, an urgent need for alternative, rapid, and sensitive immunoassays is required for primary screening of virus. In this study, we developed a smartphone-based nanozyme-linked immunosorbent assay (SP-NLISA) for detecting the specific nucleocapsid phosphoprotein (NP) of SARS-CoV-2 in 37 serum samples from 20 COVID-19 patients who were diagnosed by NAT previously. By using SP-NLISA, 28/37 (75.7%) serum samples were detected for NP antigens and no cross-reactivity with blood donors' control samples collected from different areas of China. In a control assay using the conventional enzyme-linked immunosorbent assay (ELISA), only 7/37 (18.91%) serum samples were detected for NP antigens and no cross-reactivity with control samples. SP-NLISA could be used for rapid detection of SARS-CoV-2 NP antigen in primary screening of SARS-CoV-2 infected individuals.
自2019年12月以来，一种新型冠状病毒（严重急性呼吸综合征冠状病毒2，SARS-CoV-2）引发了冠状病毒病（COVID-19）的全球大流行。尽管病毒核酸检测（NAT）主要用于检测SARS-CoV-2 RNA以确诊COVID-19，但对于病毒的初步筛查迫切需要替代的、快速且灵敏的免疫测定方法。在本研究中，我们开发了一种基于智能手机的纳米酶联免疫吸附测定法（SP-NLISA），用于检测20例先前经NAT确诊的COVID-19患者的37份血清样本中SARS-CoV-2的特异性核衣壳磷蛋白（NP）。通过使用SP-NLISA，在37份血清样本中有28份（75.7%）检测到NP抗原，且与从中国不同地区采集的献血者对照样本无交叉反应。在使用传统酶联免疫吸附测定法（ELISA）的对照试验中，仅在37份血清样本中的7份（18.91%）检测到NP抗原，且与对照样本无交叉反应。SP-NLISA可用于在SARS-CoV-2感染个体的初步筛查中快速检测SARS-CoV-2 NP抗原。
